2.23
12.20%
-0.31
After Hours:
2.23
Virpax Pharmaceuticals Inc stock is currently priced at $2.23, with a 24-hour trading volume of 40,171.
It has seen a -12.20% decreased in the last 24 hours and a -46.52% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.61 pivot point. If it approaches the $2.15 support level, significant changes may occur.
Previous Close:
$2.54
Open:
$2.41
24h Volume:
40,171
Market Cap:
$2.61M
Revenue:
-
Net Income/Loss:
$-15.19M
P/E Ratio:
-1.7023
EPS:
-1.31
Net Cash Flow:
$-9.85M
1W Performance:
-23.59%
1M Performance:
-46.52%
6M Performance:
+218.12%
1Y Performance:
+248.38%
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Name
Virpax Pharmaceuticals Inc
Sector
Industry
Phone
610 727 4597
Address
1055 Westlakes Drive, Suite 300, Berwyn
Virpax Pharmaceuticals Inc Stock (VRPX) Latest News
Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Why Getaround Shares Are Trading Higher By Around 86%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Why GitLab Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Benzinga
Virpax Pharmaceuticals Inc Stock (VRPX) Financials Data
Virpax Pharmaceuticals Inc (VRPX) Net Income 2024
VRPX net income (TTM) was -$15.19 million for the quarter ending December 31, 2023, a +29.84% increase year-over-year.
Virpax Pharmaceuticals Inc (VRPX) Cash Flow 2024
VRPX recorded a free cash flow (TTM) of -$9.85 million for the quarter ending December 31, 2023, a +44.79% increase year-over-year.
Virpax Pharmaceuticals Inc (VRPX) Earnings per Share 2024
VRPX earnings per share (TTM) was -$12.97 for the quarter ending December 31, 2023, a +29.85% growth year-over-year.
About Virpax Pharmaceuticals Inc
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Cap:
|
Volume (24h):